CETN2: A Potential Drug Target and Biomarker for Chronic Obstructive Pulmonary Disease

Target Name: CETN2

NCBI ID: G1069

CETN2

CETN2: A Potential Drug Target and Biomarker for Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide, leading to significant morbidity and mortality. Chronic inflammation of the airways and lungs can cause significant impairment in quality of life and even lead to respiratory failure. The underlying causes of COPD are not well understood, but research has identified several potential drug targets and biomarkers that may contribute to the development and progression of the disease. In this article, we will focus on CETN2, a potential drug target and biomarker for COPD.

CETN2 is a protein that is expressed in the airways of individuals with COPD. It is a member of the centrin family of proteins, which are involved in cell division, development, and function. CETN2 has been shown to be involved in the regulation of cell proliferation, apoptosis, and angiogenesis, which are critical processes that contribute to the development and progression of COPD.

COPD is a complex disease that is characterized by chronic inflammation of the airways and lungs. The airways of the lungs are lined with epithelial cells, which produce surfactant, a substance that helps to reduce surface tension and promote smooth muscle contractions. However, in individuals with COPD, the production of surfactant is decreased, leading to the accumulation of mucus in the airways. This accumulation of mucus can cause significant impairment in airflow and lead to the development of COPD symptoms.

CETN2 has been shown to be involved in the regulation of surfactant production in COPD. Studies have shown that individuals with COPD have decreased levels of CETN2 in their airways compared to individuals without COPD. Additionally, overexpression of CETN2 has been shown to decrease surfactant production in COPD airways, which may contribute to the development of COPD symptoms.

In addition to its role in surfactant production, CETN2 has also been shown to be involved in the regulation of cell apoptosis in COPD. Cell apoptosis is a natural process that is involved in the elimination of damaged or dysfunctional cells in the body. However, in individuals with COPD, the regulation of cell apoptosis is disrupted, which can contribute to the chronic inflammation of the airways and lungs.

Studies have shown that individuals with COPD have increased levels of apoptosis in their airways compared to individuals without COPD. Additionally, overexpression of CETN2 has been shown to increase apoptosis in COPD airways, which may contribute to the development of COPD symptoms.

CETN2 has also been shown to be involved in the regulation of angiogenesis in COPD. Angiogenesis is the process by which new blood vessels are formed in the body, and it is a critical process for the development and maintenance of tissues. However, in individuals with COPD, the regulation of angiogenesis is disrupted, which can contribute to the chronic inflammation of the airways and lungs.

Studies have shown that individuals with COPD have decreased levels of angiogenesis in their airways compared to individuals without COPD. Additionally, overexpression of CETN2 has been shown to decrease angiogenesis in COPD airways, which may contribute to the development of COPD symptoms.

Despite the potential involvement of CETN2 in the development and progression of COPD, much research is needed to fully understand its role in the disease. Further studies are needed to determine the exact mechanisms by which CETN2 contributes to the development and progression of COPD.

In conclusion, CETN2 is a protein that is expressed in the airways of individuals with COPD and has been shown to be involved in the regulation of surfactant production, cell apoptosis, and angiogenesis. Further research is needed to fully understand its role in the development and progression of COPD. If CETN2 is identified as a potential drug target or biomarker for COPD, it may be a valuable tool for the development of new treatments for this progressive lung disease.

Protein Name: Centrin 2

Functions: Plays a fundamental role in microtubule organizing center structure and function. Required for centriole duplication and correct spindle formation. Has a role in regulating cytokinesis and genome stability via cooperation with CALM1 and CCP110

The "CETN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CETN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets